Targeting novel regulated cell death: Ferroptosis, pyroptosis and necroptosis in anti‐PD‐1/PD‐L1 cancer immunotherapy

Cell Proliferation, Год журнала: 2024, Номер 57(8)

Опубликована: Апрель 9, 2024

Abstract Chemotherapy, radiotherapy, and immunotherapy represent key tumour treatment strategies. Notably, immune checkpoint inhibitors (ICIs), particularly anti‐programmed cell death 1 (PD1) ligand (PD‐L1), have shown clinical efficacy in immunotherapy. However, the limited effectiveness of ICIs is evident due to many cancers exhibiting poor responses this treatment. An emerging avenue involves triggering non‐apoptotic regulated (RCD), a significant mechanism driving cancer diverse treatments. Recent research demonstrates that combining RCD inducers with significantly enhances their antitumor across various types. The use anti‐PD‐1/PD‐L1 activates CD8 + T cells, prompting initiation novel forms, such as ferroptosis, pyroptosis, necroptosis. functions mechanisms anti‐PD1/PD‐L1 therapy remain insufficiently explored. This review summarises roles necroptosis It emphasises synergy between nanomaterials PD‐1/PD‐L1 induce different Furthermore, targeting signalling pathways combination therapies holds promise prospective strategy for

Язык: Английский

---

The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment

Cancer Letters, Год журнала: 2024, Номер 593, С. 216969 - 216969

Опубликована: Май 19, 2024

Язык: Английский

---

Grade ≥ 3 hematologic adverse events of immunotherapy in advanced NSCLC patients: a systematic review and meta-analysis

European Journal of Clinical Pharmacology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 22, 2025

Язык: Английский

---

Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database

Antibodies, Год журнала: 2024, Номер 13(3), С. 59 - 59

Опубликована: Июль 17, 2024

This study aimed to identify the 25 most prevalent adverse events (AEs) associated with FDA-approved immune checkpoint inhibitors (ICIs)-specifically, PD-1, PD-L1, CTLA-4, and LAG-3 inhibitors-using data from FDA Adverse Events Reporting System (FAERS), a publicly available repository of reported drug events, AERSMine, an open-access pharmacovigilance tool, investigate these events. For PD-1 inhibitors, common AEs were diarrhea, fatigue, pyrexia, notable instances neutropenia hypothyroidism, particularly toripalimab dostarlimab. PD-L1 also frequently caused interstitial lung disease hypothyroidism showing class effect, drug-specific such as hepatotoxicity chills. CTLA-4 predominantly resulted in diarrhea colitis, ipilimumab causing pyrexia rash, while tremelimumab exhibited unique biliary tract infection. The inhibitor relatlimab fewer AEs, including pneumonia. Rare but significant across all included myocarditis myasthenia gravis. provides detailed overview ICIs, offering valuable insights for clinical decision-making AE management. Further research is necessary elucidate mechanisms underlying develop targeted interventions enhance safety efficacy ICI therapy patients cancer.

Язык: Английский

---

Application of Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma: Current Status, Challenges, and Future Directions

Опубликована: Янв. 23, 2025

In recent years, immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of renal cell carcinoma (RCC), significantly enhanced patient outcomes and expanded therapeutic options beyond traditional surgical targeted approaches. this review, we provide a comprehensive review current applications ICI in RCC therapy, elucidating their mechanisms action, clinical efficacy across both clear non-clear subtypes, safety profiles. We compare effectiveness monotherapy versus combination therapies, demonstrating how synergistic approaches can improve durability responses. Furthermore, explore integration multi-omics technologies, such as single-cell RNA sequencing spatial transcriptomics, which are pivotal predicting response addressing resistance mechanisms. Our discussion also addresses critical challenges immunotherapy, including primary acquired resistance, economic ethical barriers, management immune-related adverse events. By synthesizing research findings, aims to valuable insights for optimizing fostering development more effective individualized protocols, ultimately improving survival quality life.

Язык: Английский

---

Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 25, 2025

Thyroid dysfunction is a common immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4. Nevertheless, the incidence of severe cases, defined as grade 3 or higher, remains rare. This report presents detailed case study thyroiditis in patient non-small cell lung cancer (NSCLC) who developed following single cycle sintilimab monotherapy. The clinical presentation this was remarkable for its early onset, occurring one week after initiation therapy, manifestations. During hospitalization, prompt accurate differential diagnosis performed. Sintilimab treatment discontinued, promptly started on high-dose glucocorticoids, tapering schedule implemented condition improved reached Common Terminology Criteria Adverse Events (CTCAE) 1 lower. subsequently overt hypothyroidism, necessitating thyroxine replacement therapy. Furthermore, we provide comprehensive review mechanisms risk factors thyroid events (TD-irAEs). It imperative clinicians to meticulously monitor symptoms exhibited by patients. For those presenting symptoms, appropriate symptomatic management are essential. Additionally, regular function testing recommended high-risk patients, advocate assessment baseline levels peroxidase antibodies (TPOAb) thyroglobulin (TGAb) prior initiating ICI treatment.

Язык: Английский

---

Erkennen und Behandeln von Nebenwirkungen der Immuntherapie

Deleted Journal, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

---

Autoimmune-related adverse events induced by immune checkpoint inhibitors

Current Opinion in Immunology, Год журнала: 2025, Номер 94, С. 102556 - 102556

Опубликована: Апрель 11, 2025

Язык: Английский

---

Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 11, 2024

Язык: Английский

---

Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Окт. 22, 2024

Background Chemotherapy combined with PD-1 inhibitor treatment has revolutionized the standard of care for patients NSCLC. However, benefit is not universal, highlighting need precise prediction factors. Given their relationship immune system and non-invasive nature, serum cytokines are potential candidates predicting clinical effects chemoimmunotherapy. Our study aims to evaluate association prognosis NSCLC treated Methods Levels 10 were detected in 60 receiving chemotherapy plus inhibitor-based treatment. Of these, dynamic samples from 19 collected at baseline after two cycles. Their patients’ clinicopathological characteristics, PFS OS was described investigated using survival analysis, cox regression time-dependent ROC analysis. Preliminary evaluation changes cytokine levels associated response conducted. Results Patients lower IL-6, IL-5, IL-8, TNF-α IL-10 had longer PFS, while higher IL-4 PFS. IL-22, OS, OS. Multivariate analysis suggested that IL-6 IL-5 poorer dismal Additionally, could be response. Conclusion suggests cytokines, specifically TNF-α, IL-10, IL-4, prognostic factors

Язык: Английский

---